Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies.

Cardiovascular diseases Comorbidities Heart diseases Meta-analysis Multiple sclerosis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 08 08 2021
revised: 13 09 2021
accepted: 23 09 2021
pubmed: 15 10 2021
medline: 17 12 2021
entrez: 14 10 2021
Statut: ppublish

Résumé

Observational studies have described associations between multiple sclerosis (MS) and heart diseases, but the results were mixed. Medline, Embase, and Cochrane CENTRAL were searched up to 5 October 2020 according to a protocol (PROSPERO registration number CRD42020184493). We included longitudinal non-randomized studies of exposure comparing the incidence of acquired heart diseases between people with multiple sclerosis (pwMS) and people without multiple sclerosis. We used ROBINS-E and the GRADE approach to assess risk of bias and the certainty of evidence, respectively. Data were pooled using random-effect models. Of 5,159 studies, nine studies met the inclusion criteria. MS was associated with an increased risk for myocardial infarction (HR 1.6, 95% CI 1.2 to 2.0, I2 86%, n = 1,209,079) and heart failure (HR 1.7, 95% CI 1.3 to 2.2, I2 49%, n = 489,814). The associations were more pronounced among women and younger people in subgroup analyses. We found no difference for ischemic heart disease (HR 1.0, 95% CI 0.8 to 1.4, I2 86%, n = 679,378) and bradycardia (HR 1.5, 95% CI 0.4 to 5.0, I2 50%, n = 187,810). The risk of atrial fibrillation was lower in pwMS (HR 0.7, 95% CI 0.6 to 0.8, I2 0%, n = 354,070), but the risk of bias was high, and the certainty of evidence was rated as very low. One study found more cases of infectious endocarditis among pwMS (HR 1.2, 95% CI 1.0 to 1.4, n = 83,712). Myocardial infarction and heart failure should be considered in people with multiple sclerosis during follow-up examinations.

Sections du résumé

BACKGROUND BACKGROUND
Observational studies have described associations between multiple sclerosis (MS) and heart diseases, but the results were mixed.
METHODS METHODS
Medline, Embase, and Cochrane CENTRAL were searched up to 5 October 2020 according to a protocol (PROSPERO registration number CRD42020184493). We included longitudinal non-randomized studies of exposure comparing the incidence of acquired heart diseases between people with multiple sclerosis (pwMS) and people without multiple sclerosis. We used ROBINS-E and the GRADE approach to assess risk of bias and the certainty of evidence, respectively. Data were pooled using random-effect models.
RESULTS RESULTS
Of 5,159 studies, nine studies met the inclusion criteria. MS was associated with an increased risk for myocardial infarction (HR 1.6, 95% CI 1.2 to 2.0, I2 86%, n = 1,209,079) and heart failure (HR 1.7, 95% CI 1.3 to 2.2, I2 49%, n = 489,814). The associations were more pronounced among women and younger people in subgroup analyses. We found no difference for ischemic heart disease (HR 1.0, 95% CI 0.8 to 1.4, I2 86%, n = 679,378) and bradycardia (HR 1.5, 95% CI 0.4 to 5.0, I2 50%, n = 187,810). The risk of atrial fibrillation was lower in pwMS (HR 0.7, 95% CI 0.6 to 0.8, I2 0%, n = 354,070), but the risk of bias was high, and the certainty of evidence was rated as very low. One study found more cases of infectious endocarditis among pwMS (HR 1.2, 95% CI 1.0 to 1.4, n = 83,712).
CONCLUSIONS CONCLUSIONS
Myocardial infarction and heart failure should be considered in people with multiple sclerosis during follow-up examinations.

Identifiants

pubmed: 34649134
pii: S2211-0348(21)00546-0
doi: 10.1016/j.msard.2021.103279
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103279

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Daniel Rapp (D)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany. Electronic address: daniel.rapp@uni-ulm.de.

Sebastian Michels (S)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany. Electronic address: sebastian.michels@uni-ulm.de.

Jakob Schöpe (J)

Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg, Saarland, Germany. Electronic address: schoepe@med-imbei.uni-saarland.de.

Lukas Schwingshackl (L)

Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: schwingshackl@cochrane.de.

Hayrettin Tumani (H)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany; Fachklinik für Neurologie Dietenbronn, Dietenbronn 7, 88477 Schwendi, Germany. Electronic address: hayrettin.tumani@uni-ulm.de.

Makbule Senel (M)

Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany. Electronic address: makbule.senel@uni-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH